Clinical Trials Resource Center

Kaposi's Sarcoma

March 18, 2002

Phase I trial results suggest that Metastat (COL-3) is reasonably well tolerated and produces anti-tumor activity in subjects with AIDS-related Kaposi's Sarcoma (KS). The trial included 18 subjects - 17 had experienced recurrent disease following therapy with drugs such as liposomal daunorubicin, paclitaxel and liposomal doxorubicin. Additionally, 14 of the subjects were receiving highly active anti-retroviral therapy. Results showed that eight of 18 (44%) subjects experienced tumor regression with Metastat treatment. All signs of cancer were eliminated in one subject, and in seven subjects, at least a 50% decrease in the number or size of cancer lesions was observed. Metastat is being developed by CollaGenex Pharmaceuticals.

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.